• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Novaliq’s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye disease

December 8, 2017 By Sarah Faulkner

NovaliqPrivately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe.

The treatment uses Novaliq’s water-free EyeSol drug delivery tech and is available in a multi-dose bottle. The company touted its product as the first eye drop to contain high concentrations of Omega-3 ethyl ester.

Novaliq’s NovaTears therapy combined with Omega-3 works by stabilizing the lipid layer of the tear film, reducing the evaporation of the underlying water phase and supplementing the lipid layer with Omega-3.

The company characterized its NovaTears product as the first lipid layer stabilizer that improves the signs and symptoms in patients with DED without causing vision blurring.

“It is well-known that dry eye disease compromises the lipid layer of the tear film, which, in healthy eyes, protects the tear film against evaporation,” Jerry Cagle, Alcon’s former chief scientific officer and member of Novaliq’s supervisory board, said in prepared remarks. “The addition of Omega-3 fatty acids to an already powerful NovaTears eye drop will provide dry eye patients with additional relief and physiological benefits by stabilizing the lipid layer. This will be a welcome and much-needed addition to ophthalmologists’ arsenal of DED products in Europe.”

“NovaTears as the first and only treatment specifically designed to treat evaporative DED provides high efficacy and great comfort to patients,” founder & chief innnovation officer Bernhard Günther added. “The therapeutic benefits of combining these qualities with those of Omega-3 fatty acids offer further advantages. I am confident that all dry eye patients will greatly benefit from this breakthrough innovation.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance Tagged With: Novaliq GmbH

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS